Maximizing survival and minimizing toxicity

被引：23

作者：

Brockstein, Bruce E. ^{[1
]}

Vokes, Everett E. ^{[2
]}

机构：

[1] NorthShore Univ HealthSyst, Div Hematol Oncol, Evanston, IL 60201 USA

[2] Univ Chicago, Pritzker Sch Med, Div Biol Sci, Chicago, IL 60637 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2011年 / 8卷 / 02期

关键词：

ADVANCED HEAD; NECK-CANCER; OROPHARYNGEAL CANCER; HUMAN-PAPILLOMAVIRUS; TROG; 02.02; CHEMORADIOTHERAPY; TRIAL;

D O I：

10.1038/nrclinonc.2010.226

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

outcomes for patients with oropharyngeal cancer are determined by their tumor characteristics and associated demographics. the role of human papilloma virus-related disease for prognosis and outcomes with chemoradiotherapy is being more clearly defined. egFr inhibitors are used in conjunction with radiotherapy, and the importance of optimizing radiation quality and minimizing toxicity is the focus of ongoing studies.

引用

页码：72 / 74

页数：4

共 8 条

[1] Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer [J].

Ang, K. Kian ;

Harris, Jonathan ;

Wheeler, Richard ;

Weber, Randal ;

Rosenthal, David I. ;

Nguyen-Tan, Phuc Felix ;

Westra, William H. ;

Chung, Christine H. ;

Jordan, Richard C. ;

Lu, Charles ;

Kim, Harold ;

Axelrod, Rita ;

Silverman, C. Craig ;

Redmond, Kevin P. ;

Gillison, Maura L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (01) :24-35

[2] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].

Bonner, JA ;

Harari, PM ;

Giralt, J ;

Azarnia, N ;

Shin, DM ;

Cohen, RB ;

Jones, CU ;

Sur, R ;

Raben, D ;

Jassem, J ;

Ove, R ;

Kies, MS ;

Baselga, J ;

Youssoufian, H ;

Amellal, N ;

Rowinsky, EK ;

Ang, KK .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578

[3] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].

Bonner, James A. ;

Harari, Paul M. ;

Giralt, Jordi ;

Cohen, Roger B. ;

Jones, Christopher U. ;

Sur, Ranjan K. ;

Raben, David ;

Baselga, Jose ;

Spencer, Sharon A. ;

Zhu, Junming ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Ang, K. Kian .

LANCET ONCOLOGY, 2010, 11 (01) :21-28

[4] Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer [J].

Cohen, Ezra E. W. ;

Haraf, Daniel J. ;

Kunnavakkam, Rangesh ;

Stenson, Kerstin M. ;

Blair, Elizabeth A. ;

Brockstein, Bruce ;

Lester, Eric P. ;

Salama, Joseph K. ;

Dekker, Allison ;

Williams, Rosalyn ;

Witt, Mary Ellyn ;

Grushko, Tatyana A. ;

Dignam, James J. ;

Lingen, Mark W. ;

Olopade, Olufunmilayo I. ;

Vokes, Everett E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3336-3343

[5] Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results [J].

Feng, Felix Y. ;

Kim, Hyungjin M. ;

Lyden, Teresa H. ;

Haxer, Marc J. ;

Worden, Francis P. ;

Feng, Mary ;

Moyer, Jeffrey S. ;

Prince, Mark E. ;

Carey, Thomas E. ;

Wolf, Gregory T. ;

Bradford, Carol R. ;

Chepeha, Douglas B. ;

Eisbruch, Avraham .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) :2732-2738

[6] Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02 [J].

Peters, Lester J. ;

O'Sullivan, Brian ;

Giralt, Jordi ;

Fitzgerald, Thomas J. ;

Trotti, Andy ;

Bernier, Jacques ;

Bourhis, Jean ;

Yuen, Kally ;

Fisher, Richard ;

Rischin, Danny .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) :2996-3001

[7] Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial [J].

Rischin, Danny ;

Young, Richard J. ;

Fisher, Richard ;

Fox, Stephen B. ;

Le, Quynh-Thu ;

Peters, Lester J. ;

Solomon, Ben ;

Choi, Jimin ;

O'Sullivan, Brian ;

Kenny, Lizbeth M. ;

McArthur, Grant A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4142-4148

[8] Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels [J].

Salama, J. K. ;

Stenson, K. M. ;

Kistner, E. O. ;

Mittal, B. B. ;

Argiris, A. ;

Witt, M. E. ;

Rosen, F. ;

Brockstein, B. E. ;

Cohen, E. E. W. ;

Haraf, D. J. ;

Vokes, E. E. .

ANNALS OF ONCOLOGY, 2008, 19 (10) :1787-1794

← 1 →